NeuBase Therapeutics (NASDAQ:NBSE) Shares Down 3.7%

Posted by on Jun 14th, 2023

NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Get Rating)’s share price fell 3.7% during trading on Tuesday . The company traded as low as $0.18 and last traded at $0.18. 307,205 shares were traded during trading, a decline of 26% from the average session volume of 412,828 shares. The stock had previously closed at $0.19.

NeuBase Therapeutics Stock Performance

The company has a market cap of $6.09 million, a price-to-earnings ratio of -0.24 and a beta of 1.00. The company has a fifty day moving average of $0.17 and a two-hundred day moving average of $0.21.

NeuBase Therapeutics (NASDAQ:NBSE – Get Rating) last issued its quarterly earnings results on Thursday, May 11th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Equities analysts expect that NeuBase Therapeutics, Inc. will post -0.4 EPS for the current fiscal year.

Institutional Trading of NeuBase Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its holdings in shares of NeuBase Therapeutics by 20.2% in the third quarter. Renaissance Technologies LLC now owns 287,386 shares of the company’s stock valued at $114,000 after acquiring an additional 48,255 shares in the last quarter. Worth Venture Partners LLC grew its position in NeuBase Therapeutics by 11.9% during the first quarter. Worth Venture Partners LLC now owns 256,553 shares of the company’s stock valued at $482,000 after buying an additional 27,300 shares during the period. Royal Bank of Canada increased its holdings in NeuBase Therapeutics by 64.3% during the first quarter. Royal Bank of Canada now owns 114,473 shares of the company’s stock worth $215,000 after buying an additional 44,791 shares during the last quarter. State Street Corp lifted its stake in NeuBase Therapeutics by 18.4% in the first quarter. State Street Corp now owns 68,687 shares of the company’s stock valued at $129,000 after purchasing an additional 10,674 shares during the last quarter. Finally, First Manhattan Co. purchased a new stake in NeuBase Therapeutics in the first quarter worth $26,000. 37.21% of the stock is owned by institutional investors.

NeuBase Therapeutics Company Profile

(Get Rating)

NeuBase Therapeutics, Inc, a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.

Read More

Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.